Serial Number
98978174
Owner
Flagship Labs 94, Inc.Attorney
Christina M. LicursiFirst Use Date
May 26, 2025
Filing Date
Oct 4, 2024
EXPEDITION Trademark
Serial Number: 98978174
Trademark Classes
Owner Contact Info
55 Cambridge Parkway, Suite 800E
Cambridge, MA 02142
Entity Type: 03
55 CAMBRIDGE PARKWAY, SUITE 800E
CAMBRIDGE, MA 02142
Entity Type: 03
Legal Representation
Correspondence Address
Christina M. Licursi Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, MA 02210-2206
United States
Trademark Details
Filing Date
October 4, 2024
Registration Date
Not Registered
First Use Anywhere
May 26, 2025
First Use in Commerce
May 26, 2025
Published for Opposition
September 16, 2025
Goods & Services
Pharmaceuticals for the treatment, prevention, mitigation, management, or diagnosis of cancer, and viral, bacterial, fungal, parasitic, prion-based, metabolic, endocrine, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric, immune system-related, autoimmune, genetic, rare, hematological, musculoskeletal, rheumatological, renal, nutritional, otolaryngological, pediatric, developmental, age-related, and pain-related diseases and disorders; therapeutics, namely, therapeutic agents for the treatment, prevention, mitigation, management, or diagnosis of cancer, and viral, bacterial, fungal, parasitic, prion-based, metabolic, endocrine, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric, immune system-related, autoimmune, genetic, rare, hematological, musculoskeletal, rheumatological, renal, nutritional, otolaryngological, pediatric, developmental, age-related, and pain-related diseases and disorders; protein-based and small molecule therapeutics, namely, therapeutic agents for the treatment, prevention, mitigation, management, or diagnosis of cancer, and viral, bacterial, fungal, parasitic, prion-based, metabolic, endocrine, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric, immune system-related, autoimmune, genetic, rare, hematological, musculoskeletal, rheumatological, renal, nutritional, otolaryngological, pediatric, developmental, age-related, and pain-related diseases and disorders; protein-based and small molecule pharmaceuticals for the treatment, prevention, mitigation, management, or diagnosis of cancer, and viral, bacterial, fungal, parasitic, prion-based, metabolic, endocrine, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric, immune system-related, autoimmune, genetic, rare, hematological, musculoskeletal, rheumatological, renal, nutritional, otolaryngological, pediatric, developmental, age-related, and pain-related diseases and disorders
Scientific research, namely, research and analysis services for the design and characterization of chemical therapeutic products; research services in the fields of proteomic analysis; proteomic analysis for scientific and research purposes; medical and scientific research in the field of proteomics; research and development in the field of proteomics; medical research, namely, compiling data for research purposes in the field of proteomics